Exelixis Inc Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Exelixis Inc (EXEL) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $42.60 per share for the 12-month period ending 2026-01-02, per its 10-K filed 2026-02-10.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-02-10
- Exelixis Inc share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-29 was $23.24.
- Exelixis Inc share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-04-01 was $19.02.
- Exelixis Inc share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2020-04-03 was $18.84, a 17.87% decline year-over-year.
- Exelixis Inc share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2019-03-29 was $22.94, a 10.81% decline year-over-year.
- Exelixis Inc share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2026 was $42.60, a 89.67% increase from fiscal 2025.
- Exelixis Inc share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $22.46, a 10.04% increase from fiscal 2023.
- Exelixis Inc share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $20.41, a 2.10% increase from fiscal 2022.
- Exelixis Inc share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $19.99, a 6.28% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-01-02 | $42.60 10-K · filed 2026-02-10 | |||
| 2025-01-03 | $22.46 10-K · filed 2025-02-11 | |||
| 2024-09-27 | $22.46 10-Q · filed 2024-10-29 | |||
| 2024-06-28 | $22.46 10-Q · filed 2024-08-06 | |||
| 2024-03-29 | $23.24 10-Q · filed 2024-04-30 | |||
| 2023-12-29 | $20.41 10-K · filed 2024-02-06 | |||
| 2023-09-29 | $20.41 10-Q · filed 2023-11-01 | |||
| 2023-06-30 | $19.33 10-Q · filed 2023-08-01 | |||
| 2022-12-30 | $19.99 10-K · filed 2023-02-07 | |||
| 2022-09-30 | $19.99 10-Q · filed 2022-11-01 | |||
| 2022-07-01 | $19.99 10-Q · filed 2022-08-09 | |||
| 2022-04-01 | $19.02 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | $21.33 10-K · filed 2022-02-18 | |||
| 2021-01-01 | $21.89 10-K · filed 2021-02-11 | |||
| 2020-10-02 | $21.84 10-Q · filed 2020-11-05 | |||
| 2020-07-03 | $21.40 10-Q · filed 2020-08-06 | |||
| 2020-04-03 | $18.84 10-Q · filed 2020-05-05 | |||
| 2020-01-03 | $20.08 10-K · filed 2020-02-25 | |||
| 2019-09-27 | $20.81 10-Q · filed 2019-10-30 | |||
| 2019-06-28 | $21.10 10-Q · filed 2019-07-31 | |||
| 2019-03-29 | $22.94 10-Q · filed 2019-05-01 | |||
| 2018-12-28 | $19.40 10-K · filed 2019-02-22 | |||
| 2018-09-28 | $19.52 10-Q · filed 2018-11-01 | |||
| 2018-06-29 | $22.63 10-Q · filed 2018-08-01 | |||
| 2018-03-30 | $25.72 10-Q · filed 2018-05-02 | |||
| 2017-12-29 | $23.43 10-K · filed 2018-02-26 | |||
| 2017-09-30 | $21.60 10-Q · filed 2017-11-01 | |||
| 2017-06-30 | $20.57 10-Q · filed 2017-08-02 | |||
| 2017-03-31 | $20.16 10-Q · filed 2017-05-01 | |||
| 2016-12-31 | $8.29 10-K · filed 2017-02-27 | |||
| 2016-09-30 | $7.35 10-Q · filed 2016-11-03 | |||
| 2016-06-30 | $4.63 10-Q · filed 2016-08-03 | |||
| 2016-03-31 | $4.17 10-Q · filed 2016-05-04 | |||
| 2015-12-31 | $3.78 10-K · filed 2016-02-29 | |||
| 2015-09-30 | $3.70 10-Q · filed 2015-11-10 | |||
| 2015-06-30 | $2.11 10-Q · filed 2015-08-11 | |||
| 2015-03-31 | $1.94 10-Q · filed 2015-04-30 | |||
| 2014-12-31 | $2.11 10-K · filed 2015-03-02 | |||
| 2014-09-30 | $2.13 10-Q · filed 2014-11-04 | |||
| 2014-06-30 | $5.40 10-Q · filed 2014-07-31 | |||
| 2014-03-31 | $6.96 10-Q · filed 2014-05-01 | |||
| 2013-12-31 | $5.44 10-K · filed 2015-03-02 | |||
| 2013-09-30 | $5.38 10-Q · filed 2013-10-30 | |||
| 2013-06-30 | $4.65 10-Q · filed 2013-08-06 | |||
| 2013-03-31 | $4.64 10-Q · filed 2013-05-07 | |||
| 2012-12-31 | $5.45 10-K · filed 2015-03-02 | |||
| 2012-09-30 | $5.49 10-Q · filed 2012-11-07 | |||
| 2011-12-31 | $5.86 10-K · filed 2014-02-20 | |||
| 2010-12-31 | $6.28 10-K · filed 2013-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |